Psoriatic Arthritis Therapeutics Market
The global psoriatic arthritis therapeutics market was valued at USD 14.8 billion in 2025 and is projected to reach nearly USD 25.18 billion by 2033, growing at a CAGR of 8.5% during the forecast period from 2026 to 2033.
The market is witnessing strong growth driven by the increasing prevalence of autoimmune and inflammatory disorders, rising awareness regarding early diagnosis of psoriatic arthritis, and growing demand for targeted biologic therapies worldwide. Expanding adoption of TNF inhibitors, interleukin inhibitors, JAK inhibitors, and disease modifying anti rheumatic drugs (DMARDs) is significantly improving disease management and patient outcomes across healthcare systems. In addition, advancements in precision medicine, biomarker based diagnostics, and personalized immunotherapy approaches are accelerating market expansion globally.
The market is also benefiting from continuous regulatory approvals, expanding reimbursement support, and increasing investments in autoimmune disease research by pharmaceutical companies. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) continue to support development of innovative psoriatic arthritis therapies through fast track approvals and updated rheumatology treatment guidelines. Companies including AbbVie Inc., Novartis AG, Johnson & Johnson, and Amgen Inc. are actively focusing on next generation biologics, oral targeted therapies, and expanded immunology treatment portfolios to strengthen their market presence. Furthermore, increasing clinical trial activity for novel cytokine inhibitors and growing adoption of combination therapy approaches are creating substantial growth opportunities for the psoriatic arthritis therapeutics market worldwide.
Psoriatic Arthritis Therapeutics Market Scope
| Metrics | Details |
| Market CAGR | 8.5% |
| Segments Covered | By Type, By Application, By End User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Psoriatic Arthritis Therapeutics Market Dynamics
The market is driven by an increase in the prevalence of psoriatic arthritis, new product development, a rise in adoption of biologics for the treatment of moderate to severe psoriatic arthritis, and a large patient population with unmet medical needs across the globe.
Prescribed drugs for psoriatic arthritis include immune-suppressing drugs, non-steroidal drugs, and various biologics. Biologics majorly works by stopping the inflammatory condition. Tumor necrosis factor (TNF) and interleukin (IL) inhibitors are mostly used to treat psoriatic arthritis. The current research trend depicts that more emphasis is given to biologics. Biosimilar TNF alpha inhibitors present a more significant challenge to broader uptake of Novartis’ IL-17 inhibitor, Cosentyx, and Eli Lilly’s Taltz. The companies are developing new biologics based on IL-17 inhibitors.
The high cost of the drugs, generic erosion and treatment, and lack of standardization tools for diagnosis and treatment is going to restrain the market in the forecast period.
Psoriatic Arthritis Therapeutics Market Segmentation Analysis
The global psoriatic arthritis therapeutics market can be segmented by drug class as Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARD), and biologic drugs. DMARDs is further segmented as antimalarials and corticosteroids; and the biologic drug is further segmented as TNF-alpha inhibitors, IL-inhibitors, and T cells inhibitors. By route of administration the market is segmented as oral, parenteral, and topical and by distribution channels as hospital pharmacies, retail pharmacies, and online pharmacies.
By route of administration, oral treatment is expected to dominate the psoriatic arthritis market. The Food and Drug Administration (FDA) has approved Celgene Corporation’s apremilast (Otezla), the first selective inhibitor of phosphodiesterase 4 (PDE4) prescribed for adults with moderate to severe plaque psoriasis, in March 2014. Otezla shows great improvement in the signs and symptoms of psoriatic arthritis. Otezla also offers patients and physicians a new psoriatic arthritis treatment option which increases the adoption of oral treatment.
Psoriatic Arthritis Therapeutics Market Geographical Share
Geographically, the global Psoriatic Arthritis Therapeutics market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.
North America is expected to account for the highest share of the global market by 2026. High prevalence of psoriatic arthritis, increase in adoption of biological drugs for the treatment of moderate to severe psoriatic arthritis, and anticipated new product approvals are likely to fuel the psoriatic arthritis therapeutics market in North America. According to the Centre for Disease Control and Prevention (CDC), in 2017 around 1% of the total population of North America was suffering from psoriatic arthritis. In the US, psoriatic arthritis occurs in about 2% of the population and equally among both the sexes.
According to National Psoriasis Foundation, there are about 10 genes that seem to have an important role in Caucasian individuals in terms of predisposing them to psoriatic arthritis, but those same 10 genes did not appear to have any sort of effect in the Asian population, hence psoriatic arthritis is about five times more common in people of European descent than in people of Asian descent.
Key Developments
February 2026: Rising adoption of biologics, targeted immunotherapies, and AI-enabled disease monitoring accelerated growth in the psoriatic arthritis therapeutics market across North America and Europe. Major companies including AbbVie Inc., Johnson & Johnson, Pfizer Inc., and Novartis AG expanded innovation in IL-17 and TNF inhibitor therapies.
January 2026: Increasing prevalence of autoimmune disorders and expanding healthcare access across the United States, Germany, Japan, China, and India strengthened demand for advanced psoriatic arthritis treatment solutions. Asia-Pacific emerged as the fastest growing regional market driven by improving diagnosis rates and healthcare investments.
December 2025: Growing adoption of biologic therapies and oral small molecule drugs improved long-term disease management for psoriatic arthritis patients globally. Pharmaceutical companies strengthened development of next generation JAK inhibitors and precision immunology treatments.
November 2025: Expansion of rheumatology specialty clinics and digital healthcare platforms across Europe and North America improved accessibility to psoriatic arthritis diagnosis and treatment services. Healthcare providers increasingly integrated remote patient monitoring and tele-rheumatology solutions.
October 2025: Rising advancements in biomarker-based diagnostics, personalized medicine, and regenerative immunology improved treatment precision and patient outcome monitoring globally. Research institutions accelerated innovation in targeted autoimmune disease therapies.
September 2025: Increasing collaborations between pharmaceutical companies, biotechnology firms, and research organizations accelerated clinical trials evaluating advanced biologics and combination therapies for psoriatic arthritis worldwide. Europe and Asia-Pacific strengthened investments in autoimmune disease research infrastructure.
August 2025: Growing healthcare investments and awareness regarding inflammatory arthritis disorders improved accessibility to psoriatic arthritis therapeutics across Middle East, Latin America, and Asia-Pacific regions. Governments expanded reimbursement support for biologic and specialty therapies.
July 2025: Rising demand for home-based injectable therapies and digital disease management platforms improved long-term patient adherence and treatment monitoring globally. Companies including Amgen Inc. and UCB Pharma strengthened innovation in patient-centric autoimmune care solutions.
June 2025: Increasing focus on precision immunology, early diagnosis, and advanced biologic therapies supported strong growth in the psoriatic arthritis therapeutics market worldwide. North America maintained market leadership due to advanced healthcare infrastructure, while Asia-Pacific recorded rapid growth driven by rising autoimmune disease awareness and healthcare modernization initiatives.
Psoriatic Arthritis Therapeutics Companies and Competitive Analysis
- Some of the major key players in the market are AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., Bristol-Myers Squibb Company. Few of the recent key developments of the major companies include –
- In April 2019, China Health Authority NMPA approved Cosentyx (secukinumab) for moderate-to-severe psoriatic arthritis in adult patients who are candidates for systemic therapy or phototherapy.
- In March 2019, AbbVie announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies.
- In November 2018, AbbVie announced patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Pfizer a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property
- In October 2018, Sandoz received US FDA approval for biosimilar Hyrimoz (adalimumab-adaz), used for the treatment of psoriatic arthritis.
- In October 2018, Novartis received approval from European Commission on label update for Cosentyx (secukinumab). Cosentyx is the first and only fully-human treatment that specifically inhibits interleukin-17A (IL-17A), in psoriatic arthritis.
